LentiGlobin BB305 gene therapy: Phase I data

bluebird bio reported data from 2 evaluable patients with severe sickle cell disease who had at least 3 months of follow-up in the open-label, U.S. Phase I HGB-206 trial showing that LentiGlobin BB305...